Safety, Pharmacodynamics, and Pharmacokinetics of Orally Administered BLD-2660 in Subjects With IPF
Status:
Withdrawn
Trial end date:
2020-11-05
Target enrollment:
Participant gender:
Summary
A Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate Pharmacodynamics,
Pharmacokinetics, and Safety of BLD-2660 Administered Orally in Subjects with Idiopathic
Pulmonary Fibrosis